Skip to main content
OLPX
OLPX logo

OLPX · Olaplex Holdings, Inc.

Track OLPX — free
Market Cap
$1.39B
Shares
672.04M
All earnings calls

Earnings call · FY2025 Q4

Olaplex Holdings, Inc. Q4 FY2025 Earnings Call

Olaplex Holdings, Inc. Q4 FY2025 Earnings Call

Concluded Mar 5, 2026
Mar 5, 2026 31 turns
Period
FY2025 Q4
Runtime
Sources
3 artifacts

Executive readout · one minute

What matters this quarter

Olaplex delivered flat full-year 2025 net sales of $423.0 million with 22.2% adjusted EBITDA margin, but Q4 net sales grew 4.3% to $105.1 million while adjusted EBITDA fell 26.5% to $12.9 million as SG&A surged 23.1%.

Innovation pipeline and product launches 61 2026 outlook and financial guidance 53 Premium hair care category tailwinds 21 Brand relaunch and demand generation 16 Pervala Bioscience acquisition 14 Industry category development and channel evolution 12

Management tone

Positive

Net tone +22 · moderate hedging

Grounding quotes
  • “Net sales were flat at $423 million and adjusted EBITDA margin was strong at 22.2% even as we invested to strengthen our foundation for the future.”
  • “The year ended on an encouraging note, with fourth quarter revenue growth of 4% and adjusted EBITDA outperforming expectations.”
  • “transformation is not linear, and that remains the case. But we believe that we have made great progress toward delivering long-term value creation”
  • “we will be significantly pressured in the first quarter as we are investing to support that launch”

Forward guidance

3 guided metrics

Management's latest ranges and targets are included below.

Research coverage

3 live sources

Switch sources without leaving this page or losing your listening position.

Revenue · derived Q4 $105.12M +4.3% YoY
Gross margin · derived Q4 68.0% +1.7 pp YoY
Net income · derived Q4 -$13.10M

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Q4 net sales grew 4.3% to $105.1 million, ending the year on a positive note
  • Professional channel net sales rose 18.9% to $36.8 million and Direct-To-Consumer rose 6.6% to $43.6 million in Q4
  • International Q4 net sales increased 7.6% and U.S. net sales increased 0.8%
  • Q4 gross profit margin expanded to 68.0% from 66.3%, and adjusted gross profit margin rose to 70.6% from 68.6%
  • Delivered four of the top five prestige hair care launches in the industry per Circana and acquired Pervala Bioscience to expand into additional health and beauty verticals
  • Brand health tracker showed brand awareness up 7%, sentiment up 3%, and earned media value up 14% year over year

Risks & pressure points

  • Full-year adjusted EBITDA fell 27.6% to $93.9 million and adjusted EBITDA margin contracted to 22.2% from 30.7%
  • Q4 adjusted EBITDA declined 26.5% to $12.9 million and adjusted EBITDA margin fell to 12.2% from 17.4%
  • Full-year net loss of $9.3 million versus net income of $19.5 million in 2024; Q4 net loss widened to $13.1 million from $8.8 million
  • Specialty Retail channel net sales declined 14.5% to $24.7 million in Q4 and fell 8.3% to $130.4 million for the full year
  • Q4 SG&A surged 23.1% to $65.1 million and full-year SG&A rose 33.8% to $243.1 million as the company invested behind the brand relaunch
  • CFO warned Q1 adjusted EBITDA margins will be 'significantly pressured' as the company invests to support the No. 3+ launch

Forward guidance

From the 8-K filed Mar 5, 2026.

Metric Guided
Net Sales table
Fiscal Year 2026
$414M – $435M
Adjusted Gross Profit Margin table
Fiscal Year 2026
71% – 72%
Adjusted EBITDA Margin table
Fiscal Year 2026
21% – 22%
Full-screen source Call document